In 2024, the forecasted sales of systemic hormonal preparations in Japan are expected to reach 312.08 billion JPY, with a consistent annual growth projected until 2028. From 2024 to 2028, the sales forecast shows a steady upward trend, averaging an annual growth rate of around 3% year-on-year. By 2028, sales are projected to reach 365.03 billion JPY, indicating a stable expansion within the market segment. This forecast suggests a Compound Annual Growth Rate (CAGR) of approximately 3.1% over the forecast period. The actual market size prior to this projection, as of the last known data in 2023, would provide crucial insights into understanding past growth dynamics.

Looking ahead, several trends warrant attention:

An increasing demand for specialized treatments driven by an aging population in Japan.
Regulatory changes and healthcare reforms that might impact market dynamics.
Technological advancements and innovations in drug formulations and delivery methods.
Potential challenges from generic drugs and international market competition.